Molecular mechanism of chemical-induced toxicity in fetal livers
Molecular mechanism of chemical-induced toxicity in fetal livers
批准号:
17390034
负责人:
YAMAZAKI Hiroshi
金额:
$10.07万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2007
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We found several new results of drug metabolism in human liver microsomes. 1) Voriconazole ((2R, 3S)-2-(2, 4-difluorophenyI)-3-(5-fluoro-4-pyrimidiny1)-1-(1H-1, 2, 4-triazol-1-yl)-2-butanol) is a new antifungal agent developed as oral and intravenous formulations. In vivo studies in humans have indicated that voriconazole is extensively metabolized with less than 2% of the dose excreted unchanged. Involvement of cytochrome CYP2C19, CYP2C9, and CYP3A4 in N-oxidation of voriconazole has been demonstrated using human liver microsomes. To confirm the precise roles of P450 isoforms in voriconazole clearance in individuals, we investigated the oxidative metabolism of voriconazole catalyzed by recombinant P450s as well as human liver microsomes genotyped for the CYP2C19 gene. Among recombinant P450 isoforms using Escherichia coli expression systems, CYP2C19 and CYP3A4 had voriconazole N-oxidation activities, but not CYP2C92) Propofol (2, 6-diisopropylphenol) is administered for the induction … More of anesthesia and maintenance of anesthesia or for sedation. The merit of rapid and complete recovery that occurs even after relatively prolonged intravenous infusions of propofol is attributable to the extensive biotransformation of the parent compound, primarily in the liver. However, a significant association with the development of progressive myocardial failure has been reported for long-term and high-dose propofol infusion. Although there are several reports on the propofol pharmacokinetics and drug interactions in humans, the roles of individual P450 enzymes in the propofol disposition are still unknown. In the present study, the roles of human P450 enzymes involved in propofol 4- and ω-hydroxylation were investigated with recombinant human P450s and liver microsomes. CYP2B6 and CYP1A2, followed CYP3A4, showed high activities of propofol 4-hydroxylation in recombinant human P450 enzyme systems. In the contrast, ω-hydroxylation of propofol was mainly catalyzed by CYP2B6.3) Thalidomide is a promising drug in the treatment of a number of cancers and inflammatory diseases. On the other hand, a little information was reported regarding effects on metabolizing enzymes. We investigated the effects of thalidomide on cytochrome P450 in human liver microsomes. The present results suggest that total midazolam clearance would be increased in a dose dependent manner. Thalidomide may cause drug interactions of co-administered medicines Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.2174/187231207779814355
发表时间:
2007-01-01
期刊:
Drug metabolism letters
影响因子:
--
作者:
[Shimizu, Makiko, Matsumoto, Yoshiaki, Yamazaki, Hiroshi]
通讯作者:
Yamazaki, Hiroshi
Genetic polymorphism of bile acid CoA:amino acid N-acyitransferase in Japanese in dividuals
日本人胆汁酸CoA:氨基酸N-酰基转移酶基因多态性
DOI:
--
发表时间:
2007
期刊:
Drug Metab Pharmacokinet. 22
影响因子:
--
作者:
[Tougou, K., Fukuda, T., Ito, T., Yamazaki, H., and Azuma, J.]
通讯作者:
J.
ヒト肝チトクロームP450触媒活性に及ぼすサリドマイドの影響
沙利度胺对人肝细胞色素P450催化活性的影响
DOI:
--
发表时间:
2008
期刊:
影响因子:
--
作者:
[村山 典恵, 柳田 千裕, 清水 万紀子, 山崎 浩史]
通讯作者:
山崎 浩史
Voriconazole methyl hydroxylation and N-oxidation catalyzed by CYP3A4 and CYP2C19 in human liver microsomes
CYP3A4和CYP2C19在人肝微粒体中催化伏立康唑甲基羟基化和N-氧化
DOI:
--
发表时间:
2008
期刊:
影响因子:
--
作者:
[Hiroshi, Yamazaki, Node, Murayama, Naoko, Imai, Takahisa, Nakane, Makiko, Shimizu]
通讯作者:
Shimizu
臨床薬理研究進行財団
临床药理学研究进展基金会
DOI:
--
发表时间:
2007
期刊:
影响因子:
--
作者:
[山崎 浩史, 清水 万紀子, 永島 里美, 村山 典恵]
通讯作者:
村山 典恵
共 58 条
Relevance to bioactivation and toxicity of thalidomide, pomalidomide, and lenalidomide by human cytochrome P450 3A enzymes in cultured placental cells and humanized-liver mice
-
批准号:17K08425
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2017
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Mechanisms of resistance to molecularly targeted drugs for oral squamous cell carcinoma and investigation of countermeasures
-
批准号:16K11732
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.08万
-
财政年份:2016
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Development of Effective Markers for Resistance of Oral Squamous Cell Carcinoma to Molecular-targeting Drugs
-
批准号:25463120
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.16万
-
财政年份:2013
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Thalidomide increases cytochrome P450 activity and drug metabolism in liver through direct activation of nuclear receptor CAR and PXR
-
批准号:23590200
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.49万
-
财政年份:2011
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
evaluationofeffectivenessoftheobjectiveexaminationforautism indeafchildren
-
批准号:22791642
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$2.5万
-
财政年份:2010
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Role of cancer stem cells related molecules in oral squamous cell carcinoma
-
批准号:22592246
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2010
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Molecular Mechanisms of Toxic Expression Induced by Endocrine Disruptors via AHR
-
批准号:15390040
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.64万
-
财政年份:2003
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Study on the separation of rac and meso isomers and the reactivity of group 4 bridged metallocene complexes
-
批准号:11640544
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$0.38万
-
财政年份:1999
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
PREDICTION OF DRUG DISPOSITION BY HUMAN DRUG METABOLIZING ENZYMES
-
批准号:11557191
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$3.01万
-
财政年份:1999
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Creation of Substitution Labile Pyrazolylborate Metal Complexes
-
批准号:09640675
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$0.96万
-
财政年份:1997
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
底物杂泛性的P450氧化酶的理性改造及其在倍半萜C-H键活化中的应用
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:饶历
-
依托单位:
细菌特殊萜合成酶及P450酶的挖掘与功能研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
白腐真菌Pleurotus ostreatus细胞色素P450酶在药物活性化合物降解中的作用与机制研究
-
批准号:2025JJ50102
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:卓睿
-
依托单位:
基于细胞色素P450/PPAR/ROS信号通路探究丹参酮IIA 抑制骨丢分子机理
-
批准号:JCZRLH202500148
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
P450酶定向进化实现紫杉醇前体高选择性合成及其机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:张远
-
依托单位:
酸性磷酸酶与细胞色素P450还原酶协同驱动微藻降解有机磷过程及作用机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:30.0万元
-
批准年份:2024
-
负责人:汪翔
-
依托单位:
槲皮素通过 P450/BCL2/Beclin1 促进线粒体自
噬调控 M1/M2 缓解炎性损伤改善心肌缺血再
灌注损伤的机制研究
-
批准号:LSSY24H020004
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:胡赛玲
-
依托单位:
P450酶介导茶翅蝽聚集信息素生物合成的分子机制
-
批准号:32360665
-
项目类别:地区科学基金项目
-
资助金额:32万元
-
批准年份:2023
-
负责人:李峰奇
-
依托单位:
新型细胞色素P450 2D6(CYP2D6)变异体的功能及其酶动力学特征研究
-
批准号:LTGC23H310001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:钱建畅
-
依托单位:
细胞色素P450基因CYP81E介导稗草抗ACCase抑制剂类除草剂的分子机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:
-
依托单位: